

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Scythian Biosciences Corp. (the "Issuer").

Trading Symbol: SCYB

Number of Outstanding Listed Securities: 49,037,218

Date: October 4, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On September 27, 2018, the Issuer sold Company's Latin American and Caribbean assets to Aphria Inc. ("Aphria") for 15,678,310 Aphria common shares. Aphria also assumed \$1,000,000 USD in aggregate debt owing to the Issuer. As a closing condition, 350,000 of the consideration shares have been held back and will be released to the Issuer upon the post-closing satisfaction of \$5,000,000 USD obligation owing to Colcanna SAS by Issuer. This sale will provide Issuer with leverage for early stage investments in emerging U.S. markets.

During September 2018, the Issuer acquired 49% of Marigold Acquisitions Inc for 6,000,000 common shares at a price of \$3.00 and 100% of MMJ International Investments Inc. ("MMJ International") for 6,176,320 common shares at a price of \$4.40. These businesses were included as part of the sale to Aphria.

On September 14, 2018, the Issuer received shareholder approval to change its name to SOL Investments Corp. As of the date of this report the name change has not yet been implemented.

- 2. Provide a general overview and discussion of the activities of management.**

On September 27, 2018, management finalized strategic sale of the Issuer's Latin American and Caribbean assets to Aphria Inc.

The Issuer continues to work towards its acquisition of its previously announced investment in CannCure Investments Inc.

- 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None to report in the month of September.

- 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None to report in the month of September.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None to report in the month of September.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None to report in the month of September.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

Acquisitions

On September 13, 2018, the Issuer completed its acquisition of Marigold Acquisitions Inc., a privately-held British Columbia incorporated company, which indirectly holds a 49% stake in Marigold Projects Jamaica Limited. The Issuer purchased all outstanding common shares of Marigold Acquisitions in exchange for 6,000,000 common shares of the Issuer to the selling shareholders.

On September 21, 2018, the Issuer completed its acquisition of MMJ International, a privately-held British Columbia company that owns 100% of ABP S.A. In accordance with the terms and conditions of an amended and restated share purchase agreement dated September 20, 2018 between the Issuer, LATAM Holdings Inc. ("LATAM") (which was a wholly owned subsidiary of the Issuer), MMJ International and all of the shareholders of MMJ International, the Issuer, through LATAM, purchased all of the issued and outstanding common shares of MMJ International. In consideration, the shareholders of MMJ International received 6,176,320 common shares.

Disposition

On September 27, 2018, the Issuer closed a sale of its Latin American and Caribbean assets to Aphria. Pursuant to a definitive share purchase agreement dated July 17, 2018 between Aphria and the Issuer, the Issuer sold 100% of the issued and outstanding common shares of LATAM, a direct, wholly-owned

subsidiary, which had previously acquired ownership of licenses and other assets held through subsidiaries in Argentina, Colombia and Jamaica. Pursuant to the Transaction, Aphria indirectly acquired the following interests from Scythian:

(1) 49% of Marigold Projects Jamaica Limited (“Marigold Projects”). Marigold Projects has received licenses to cultivate and conditional licenses to process, sell and provide therapeutic or spa services using cannabis products in Jamaica;

(2) 100% of ABP S.A., an Argentinean pharmaceutical import and distribution company, which supported several university hospitals, to secure an import permit for cannabis oil; and

(3) 90% of Colcanna S.A.S., a Colombian medical cannabis producer, currently licensed for cultivation and importation of THC and CBD, extraction, production, research and exportation of medical cannabis products.

The Issuer also granted Aphria the right to purchase in one or more separate tranches, up to 90% of the issued and outstanding common shares of an entity in Brazil (which Scythian is seeking to acquire) that is pursuing a Brazilian medical cannabis license. Under the terms of the Agreement and as consideration for the Transaction, Aphria issued 15,678,310 shares and assumed USD \$1 million in aggregate liabilities owing to Issuer. As a closing condition, 350,000 of the Consideration shares have been held back and will be released to Issuer upon the post-closing satisfaction of a US\$5,000,000 obligation owing to Colcanna SAS.

8. Describe the acquisition of new customers or loss of customers.

None to report in the month of September.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report in the month of September.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Andrew DeFrancesco was appointed to the Board of Directors effective September 4, 2018.

Peter Liabotis was appointed as Chief Financial Officer replacing Jonathan Held effective September 28, 2018.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report in the month of September.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report in the month of September.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

As part of the Aphria transaction, 350,000 of the Consideration shares have been held back and will be released to Issuer upon the post-closing satisfaction of a US\$5,000,000 obligation owing to Colcanna SAS.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Shares	6,000,000	Acquisition of Marigold projects Jamaica	No cash consideration received
Common Shares	6,176,320	Acquisition of MMJ International Investments	No cash consideration received
Options	100,000	Issued to Director	No cash consideration received
DSU's	400,000	Issued to Chairman	No cash consideration received
Options	255,000	Issued to new CFO	No cash consideration received
DSU's	11,765	Issued to new CFO	No cash consideration received
Options	45,000	Issued to new Controller	No cash consideration received

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None to report in the month of September.

16. Provide details of any changes in directors, officers or committee members.

On September 4, 2018, Andrew DeFrancesco was appointed to the Board of Directors.

On September 28, 2018, Peter Liabotis was appointed as Chief Financial Officer replacing Jonathan Held.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There were no other significant trends or risks in the month of September.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 4, 2018.

Peter Liabotis
Name of Director or Senior Officer

/s/ "Peter Liabotis"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer Scythian Biosciences Corp.		For Month End September	Date of Report YY/MM/D 18/10/04
Issuer Address 5600-100 King St. W			
City/Province/Postal Code Toronto, ON, M5X 1C9		Issuer Fax No. ()	Issuer Telephone No. (212) 729-9208
Contact Name Peter Liabotis		Contact Position CFO	Contact Telephone No. (212) 729-9208
Contact Email Address info@scythianbio.com		Web Site Address www.scythianbio.com	